Imatinib mesylate (Gleevec), a tyrosine kinase inhibitor (TKI) targeting BCR-ABL fusion oncoprotein for treating Ph+ chronic myelogenous leukemia (CML) (1), is considered as the first targeted agent for this approach. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.